Table 2.
Treatment regimen summary and tumor mutation analysis results.
| Patient ID | Treatment #1 | Treatment #2 | Treatment #3 | Treatment #4 | Treatment #5 | Treatment #6 | Treatment #7 | NGS |
|---|---|---|---|---|---|---|---|---|
| BE1 | B + E | Sunitinib | CGB | - | - | - | - | N/A |
| BE2 | TC | B + E | CGB | - | - | - | - | N/A |
| BE3 | GD | GC + Imatinib | ddMVAC | GD + Ifos | B + E | - | - | N/A |
| BE4 | GDI | Ipi/Nivo | TC | CGI | B + E | - | - | None |
| BE5 | TC | GDI | B + E | - | - | - | - | None |
| BE6 | T | Pembro | TC | B + E | VVC | GDI | CGI | NF2 |
| BE7 | TC | GDI | B + E | - | - | - | - | None |
| BE8 | TC | T | GDI | Ipi/Nivo | CGI | B+E | - | None |
| BE9 | TC | GDI | B + E | --- | - | - | - | None |
| BE10 | Pembro | TC | GDI | B + E | - | - | - | N/A |
NGS, OncoMine next generation sequencing; N/A, not available; B + E, bevacizumab plus erlotinib; CGB, capecitabine, gemcitabine, and bevacizumab; TC, paclitaxel and carboplatin; GD, gemcitabine and doxorubicin; GC, gemcitabine and cisplatin; ddMVAC, dose dense methotrexate, vincristine, doxorubicin, and cisplatin; Ifos, ifosfamide; GDI, gemcitabine, doxorubicin, and ixazomib; Ipi/Nivo, ipilimumab plus nivolumab; CGI, cisplatin, gemcitabine, and ifosfamide; T, tazemetostat; Pembro, pembrolizumab; VVC, veliparib, Vx-970, and cisplatin; NF2, truncating NF2 single nucleotide variation.